Difficulty: Medium
Average Score: 90%
Practice
A patient to be commenced on oral anticoagulant therapy for DVT would be treated with: I. Oral anticoagulant therapy with warfarin for a goal international normalized ratio (INR) of 2-3 II. Oral anticoagulant therapy with warfarin for a goal INR of 2.5-3.5 III. Oral anticoagulant therapy with aspirin for a goal INR of 2-3
Correct answer
A
Rationale
In the context of hematology and anticoagulant therapy for Deep Vein Thrombosis (DVT), the correct answer is option A) If I only is correct.
1. **Explanation of Correct Answer**:
- Warfarin is the oral anticoagulant of choice for DVT treatment, with a target INR range of 2-3. This range ensures adequate anticoagulation to prevent clot formation without increasing the risk of bleeding complications.
2. **Explanation of Incorrect Options**:
- Option B) If III only is incorrect because aspirin is an antiplatelet agent, not an anticoagulant, and is not the primary treatment for DVT.
- Option C) If I and II are incorrect because a target INR range of 2.5-3.5 (option II) is too high and increases the risk of bleeding without additional benefit for DVT treatment.
- Option D) If II and III are incorrect for the reasons mentioned above regarding aspirin and the higher INR range.
3. **Educational Context**:
- Understanding the appropriate anticoagulant therapy and target INR range is crucial in managing DVT to prevent complications like pulmonary embolism. It is essential for healthcare professionals to be well-versed in the correct medications and dosages to optimize patient outcomes.
In conclusion, selecting the appropriate anticoagulant therapy with the correct target INR range is fundamental in the management of DVT to balance the risks of clot formation and bleeding complications effectively.
1. **Explanation of Correct Answer**:
- Warfarin is the oral anticoagulant of choice for DVT treatment, with a target INR range of 2-3. This range ensures adequate anticoagulation to prevent clot formation without increasing the risk of bleeding complications.
2. **Explanation of Incorrect Options**:
- Option B) If III only is incorrect because aspirin is an antiplatelet agent, not an anticoagulant, and is not the primary treatment for DVT.
- Option C) If I and II are incorrect because a target INR range of 2.5-3.5 (option II) is too high and increases the risk of bleeding without additional benefit for DVT treatment.
- Option D) If II and III are incorrect for the reasons mentioned above regarding aspirin and the higher INR range.
3. **Educational Context**:
- Understanding the appropriate anticoagulant therapy and target INR range is crucial in managing DVT to prevent complications like pulmonary embolism. It is essential for healthcare professionals to be well-versed in the correct medications and dosages to optimize patient outcomes.
In conclusion, selecting the appropriate anticoagulant therapy with the correct target INR range is fundamental in the management of DVT to balance the risks of clot formation and bleeding complications effectively.